Eczema Drug Nemluvio Showed Three-Year Efficacy
Long-term data suggests adults and adolescents using Nemluvio saw sustained skin and itch relief.
Updated on Sept. 30, 2026 in Asthma
Live Poll
Do you trust the long-term safety data provided by pharmaceutical companies for new skin medications?
Results from the three-year ARCADIA study showed that patients 12 and older treated with the drug Nemluvio maintained significant improvements in eczema severity. These findings, presented at the 2026 EADV Congress, provide new insights for those managing chronic skin conditions.
Why it matters
Understanding long-term treatment outcomes is critical for patients managing chronic, inflammatory skin diseases that require ongoing therapy. This study offers evidence regarding the durability of a treatment that is currently available in over 40 countries.
In this 152-week open-label extension study, researchers evaluated the safety and efficacy of Nemluvio in patients aged 12 and older. The findings demonstrate that high rates of skin clearance and symptom relief were maintained consistently over the three-year duration.
The players
Galderma
A pharmaceutical company specializing in dermatological treatments and the developer of Nemluvio.
EADV Congress
An international professional medical meeting focused on the latest developments in dermatology and venereology.
The details
Nemluvio works by targeting and inhibiting IL-31 signaling, a key pathway involved in the inflammatory response and persistent itch sensation common in eczema. By blocking this specific cytokine activity, the treatment aims to reduce both the physical severity of skin lesions and the associated urge to scratch. The study results suggest that this inhibitory mechanism remains effective and safe throughout multi-year treatment periods.
Timeline
2016: Galderma obtained exclusive rights to nemolizumab.
October 1, 2026: Clinical trial data was presented at the EADV Congress.
Health Landscape
The shift toward targeted biological therapies like IL-31 inhibitors has redefined the standard of care for chronic inflammatory skin conditions. This data from the ARCADIA study contributes to a growing body of evidence supporting the long-term management of eczema through sustained pathway inhibition.
If you are currently managing eczema, these long-term findings may be worth discussing with your dermatologist to understand if targeted biological treatments align with your care plan. Always review your medical history and treatment goals with a physician before evaluating new options.
The takeaway
The study confirms that the clinical benefits of this eczema treatment were maintained over a three-year period. Keep track of your symptom patterns and discuss any changes in itch severity or skin quality with your healthcare provider during your next checkup.
Further reading
For more information on managing chronic inflammatory conditions, see our Asthma section.
Live Poll
Do you trust the long-term safety data provided by pharmaceutical companies for new skin medications?
